The trial will assess the therapy’s pharmacokinetics, pharmacodynamics and safety, as well as its impact on disease activity.

Cullinan Therapeutics, Inc., a biopharmaceutical company focused on developing modality-agnostic targeted therapies, announced that the European Medicines Agency (EMA) approved the company’s Clinical ...

Cullinan Therapeutics (CGEM) announced that the European Medicines Agency, EMA, approved the Company’s Clinical Trial Application, CTA, for CLN-978. The Phase 1 clinical trial will assess CLN ...

Cullinan Therapeutics, Inc. has announced the European Medicines Agency's approval of its Clinical Trial Application for CLN-978, a CD19-targeting bispecific T cell engager, aiming to initiate a ...